The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...

Scholar Rock said on Wednesday its experimental drug helped overweight patients preserve more lean mass in a mid-stage trial when used in combination with Eli Lilly's weight-loss treatment Zepbound.